Skip to main content

Table 2 Paired recipients who received graft donations from the same donors stratified by MSC

From: Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal allografts: pilot results of a multicenter randomized controlled trial

Recipient characteristics (paired) Trials Control P value
Age (years) 40.8 ± 9.2 47.1 ± 10.2 0.60
Sex
 Male 14 11 0.53
 Female 7 10
Preoperative Cr (μmol/L) 1106.4 ± 326.9 967.3 ± 236.0 0.28
Previous transplants
 First transplant 20 21 1
 Second transplant 1 0
HLA mismatches
 Level 1 11 9 0.76
 Level 2 10 12
Pre-emptive dialysis vintage (years) 2.4 ± 2.2 2.1 ± 1.6 1
Cold ischemia time (h)
 < 6 14 13 1
 6–12 7 8
Postoperative complications
 DGF 2 7 0.13
 AR 3 1 0.61
 Complicated urinary tract infection 1 1 1
 Severe pneumonia 2 5 0.41
 Severe bleeding 0 0 1
 Renal allograft resection or embolism 1 1 1
 Other 1 1 1
  1. MSC mesenchymal stem cell, Cr creatinine, HLA human leukocyte antigen, DGF delayed graft function, AR acute rejection